• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    Apixaban Market

    ID: MRFR/HC/33300-HCR
    128 Pages
    Rahul Gotadki
    October 2025

    Apixaban Market Research Report By Application (Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism), By Formulation (Tablets, Intravenous), By Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies), By End Use (Inpatient, Outpatient) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Apixaban Market Infographic
    Purchase Options

    Apixaban Market Summary

    The global Apixaban market is projected to experience substantial growth from 6.49 USD billion in 2024 to 14.45 USD billion by 2035.

    Key Market Trends & Highlights

    Apixaban Key Trends and Highlights

    • The market is expected to grow at a compound annual growth rate of 7.54 percent from 2025 to 2035.
    • By 2035, the Apixaban market is anticipated to reach a valuation of 14.4 USD billion.
    • In 2024, the market valuation stands at 6.49 USD billion, indicating a strong growth trajectory.
    • Growing adoption of Apixaban due to its efficacy in preventing thromboembolic events is a major market driver.

    Market Size & Forecast

    2024 Market Size 6.49 (USD Billion)
    2035 Market Size 14.45 (USD Billion)
    CAGR (2025-2035) 7.54%

    Major Players

    AstraZeneca, Merck and Co, Sanofi, Eli Lilly and Company, AbbVie, Bristol Myers Squibb, Teva Pharmaceutical Industries, Boehringer Ingelheim, Gilead Sciences, Mylan, Roche, Johnson and Johnson, Pfizer, Novartis, Amgen

    Apixaban Market Trends

    The Global Apixaban Market is steered by an increased adoption of anticoagulation therapies with the underlying pathological conditions like atrial fibrillation and venous thromboembolism being common. Coupled with this growing demand is the focus on patient’s protection and the advantages related to the use of apixaban like its effectiveness and the lower tendency of bleeding as compared to other conventional anticoagulants. Also, a significant increase of the elderly populations coupled with changes in their lifestyles increases the instances of thrombotic events making the use of apixaban favorable by the healthcare providers.

    There are various opportunities that can be exhausted within the apixaban market.

    There exist opportunities for new formulation and delivery development as the pharmacological research still advances, thus enhancing the current treatment space. In addition, the increased availability of apixaban in the developing countries will also be an important factor for growth. They can also concentrate on forming strategic partnerships, which could boost their market share and facilitate patient access to medications. Also a competitive edge can be garnered through the sustained development of treatment plans that embrace the use of apixaban with the inclusion of other drugs.

    This is because recent patterns show that there has been a movement towards the customization and personalization of medicine which will improve the management of patients on apixaban.

    The trend is shifting towards the conception of the treatment plan where patients’ needs are put first, and side effects are paid attention to as well. Furthermore, digital health solutions are being adopted that enable patients to be better managed and to adhere to therapy and medication schedules. Increasing trend of telemedicine and remote patient monitoring makes it easier to provide timely treatment without misuse of apixaban. Such developments seem to augur well for expansion of the global apixaban market.

    The increasing prevalence of atrial fibrillation and venous thromboembolism is driving a notable rise in the demand for Apixaban, as healthcare providers seek effective anticoagulation therapies to enhance patient outcomes.

    U.S. Food and Drug Administration (FDA)

    Apixaban Market Drivers

    Market Growth Projections

    The Global Apixaban Market Industry is expected to witness substantial growth, with projections indicating a market size of 6.49 USD Billion in 2024 and an anticipated increase to 14.4 USD Billion by 2035. This growth trajectory, characterized by a CAGR of 7.54% from 2025 to 2035, underscores the increasing demand for effective anticoagulant therapies. Factors such as the rising prevalence of thromboembolic disorders and the aging population are likely to contribute to this expansion. The market dynamics suggest a robust future for Apixaban, driven by both clinical and demographic trends.

    Growing Geriatric Population

    The demographic shift towards an aging population significantly influences the Global Apixaban Market Industry. As individuals age, the risk of thromboembolic events increases, necessitating effective anticoagulation therapies. By 2035, the market is expected to expand to 14.4 USD Billion, reflecting the rising need for treatments tailored to older adults. Apixaban, with its favorable safety profile and ease of use, is becoming a preferred choice among healthcare providers. This trend indicates that as the geriatric population continues to grow, the demand for Apixaban will likely follow suit, reinforcing its market position.

    Rising Awareness and Education

    Increasing awareness and education regarding anticoagulant therapies are vital drivers for the Global Apixaban Market Industry. As healthcare professionals and patients become more informed about the benefits and risks of anticoagulation, the adoption of Apixaban is likely to rise. Educational initiatives aimed at both patients and providers can lead to improved management of conditions requiring anticoagulation, thus enhancing the market's growth potential. This trend indicates that as awareness continues to grow, the demand for Apixaban may increase, contributing to its overall market expansion.

    Advancements in Drug Formulation

    Innovations in drug formulation and delivery systems are transforming the Global Apixaban Market Industry. Enhanced formulations that improve bioavailability and patient compliance are emerging, making Apixaban more appealing to both patients and healthcare providers. These advancements may lead to increased prescriptions and usage, as patients prefer medications that are easier to take. With the market projected to grow significantly in the coming years, such innovations could play a crucial role in driving the demand for Apixaban, suggesting a positive outlook for its market trajectory.

    Regulatory Approvals and Guidelines

    The endorsement of Apixaban by regulatory bodies and its inclusion in clinical guidelines are pivotal for the Global Apixaban Market Industry. Regulatory approvals enhance the drug's credibility and accessibility, encouraging healthcare providers to prescribe it. As guidelines evolve to recommend Apixaban for various indications, including venous thromboembolism, the market is poised for growth. The anticipated compound annual growth rate (CAGR) of 7.54% from 2025 to 2035 suggests that as more healthcare professionals adopt these guidelines, the demand for Apixaban will likely increase, further solidifying its market presence.

    Rising Prevalence of Atrial Fibrillation

    The increasing incidence of atrial fibrillation globally is a primary driver for the Global Apixaban Market Industry. Atrial fibrillation affects millions, leading to a heightened demand for effective anticoagulants. In 2024, the market is projected to reach 6.49 USD Billion, driven by the need for innovative treatments. As healthcare systems worldwide prioritize managing this condition, the adoption of Apixaban is likely to rise. The drug's efficacy in reducing stroke risk in patients with atrial fibrillation positions it favorably within the market, suggesting a robust growth trajectory as awareness and diagnosis improve.

    Market Segment Insights

    Apixaban Market Segment Insights:

    Apixaban Market Segment Insights:

    Apixaban Market Application Insights 

    Apixaban Market Application Insights 

    The Global Apixaban Market revenue reflects a significant growth trajectory, particularly within the Application segment, which comprises critical areas such as Atrial Fibrillation, Deep Vein Thrombosis, and Pulmonary Embolism. In 2023, the total market value is noted at 5.62 USD Billion, with Atrial Fibrillation holding a notable share of 2.24 USD Billion, reflecting its crucial role in anticoagulant therapies.

    This condition is predominant in patients with cardiovascular abnormalities, which necessitate efficient management of blood clot risks, thus driving demand for Apixaban therapies.The Deep Vein Thrombosis sector contributes 1.68 USD Billion, highlighting its importance as a disorder characterized by blood clots in the deep veins, commonly affecting the legs. The treatment and management of this condition support considerable market growth, driven by increasing awareness and advancements in healthcare. Meanwhile, Pulmonary Embolism, valued at 2.7 USD Billion, also plays a significant role, as this condition arises when a blood clot travels to the lungs, causing life-threatening consequences.

    The combined market data reveals that Atrial Fibrillation holds a majority share as it is commonly prevalent among the aging population, raising its clinical relevance and influencing treatment strategies.Domestic and global health trends point towards escalating geriatric populations, thus creating opportunities in the Apixaban Market industry that are likely to be capitalized upon through research and development investments, aiming to enhance treatment regimens. However, challenges persist, particularly in terms of regulatory hurdles and market access in emerging regions that could inhibit the growth.

    The collective Global Apixaban Market statistics reflect a dynamic landscape where opportunities abound, underpinned by rising patient populations and ongoing technological advancements.The increasing prevalence of Atrial Fibrillation and the rising incidence of thrombotic events make these applications stand out within the global market framework, showcasing potential avenues for growth and innovation.

    Apixaban Market Formulation Insights 

    Apixaban Market Formulation Insights 

    The Global Apixaban Market is expected to reach a valuation of 5.62 USD billion in 2023, driven by the growing demand for effective anticoagulant therapies. Within the Formulation segment, the market exhibits substantial growth potential across various forms, with Tablets and Intravenous formulations gaining notable traction. Tablets have been pivotal due to their convenience and widespread acceptance by patients, allowing for improved adherence to treatment regimens.

    Intravenous formulations, on the other hand, cater specifically to hospital settings, providing immediate anticoagulation effects in critical care scenarios.This diverse segmentation of the Global Apixaban Market reflects an increasing trend towards tailored therapies that cater to different patient needs, enhancing treatment outcomes. The combination of a significant market size, along with ongoing innovations in formulation technologies, contributes to the overall market growth, presenting both opportunities and challenges in terms of regulatory approvals and competitive dynamics. Increased awareness of thromboembolic diseases further elevates the relevance of the Global Apixaban Market, positioning it favorably for expansion in the coming years.

    Apixaban Market Distribution Channel Insights 

    Apixaban Market Distribution Channel Insights 

    The Global Apixaban Market, valued at 5.62 USD Billion in 2023, is categorized into several distribution channels, with each channel playing a vital role in market accessibility and growth. Hospitals represent a significant segment, as they are primary settings for patient care and the administration of Apixaban. This channel is pivotal due to its direct interaction with healthcare professionals who prescribe the medication.

    Retail Pharmacies also hold a major share, providing patients with convenient access to Apixaban, thereby influencing consumer purchasing behavior.Additionally, the rise of Online Pharmacies is reshaping the distribution landscape, making it easier for patients to acquire medications from the comfort of their homes. This shift reflects the growing trend towards digital healthcare solutions. The ongoing increase in cardiovascular diseases and the demand for anticoagulant treatments are key growth drivers within the Global Apixaban Market. Ensuring effective distribution channels will enhance market penetration and meet the rising patient needs within this expanding industry.

    Overall, the interplay of these channels is essential for leveraging market growth while addressing consumer trends and preferences.

    Apixaban Market End Use Insights 

    Apixaban Market End Use Insights 

    The Global Apixaban Market revenue is showing promising growth, with a significant portion driven by the End Use segment. In 2023, the market valuation stood at approximately 5.62 billion USD, reflecting the increasing demand for effective anticoagulants. The End Use segment is categorized primarily into Inpatient and Outpatient, where each plays a crucial role in patient management. The Inpatient sector is pivotal as it typically encompasses those requiring immediate and intensive care.

    This necessity drives higher utilization rates, making it a critical area for market development.Conversely, the Outpatient segment is also gaining traction due to rising preventive measures and the increasing prevalence of conditions leading to thromboembolic events. The shift towards outpatient care is significant as it supports the trend of early discharge and at-home management of chronic conditions. Overall, the Global Apixaban Market segmentation reveals a balanced demand between these areas, with trends indicating that both Inpatient and Outpatient care will continue to grow, shaping the future dynamics of the Global Apixaban Market industry.

    Get more detailed insights about Apixaban Market Research Report — Global Forecast till 2034

    Regional Insights

    The Global Apixaban Market revenue in 2023 is 5.62 billion USD, showcasing a healthy trajectory with significant regional contributions. North America stands as a dominant market, valuing 2.2 billion USD in 2023 and expected to grow to 4.3 billion USD by 2032, highlighting its majority holding within the overall market. Europe follows as another important region, valued at 1.5 billion USD in 2023 and projected to reach 2.8 billion USD by 2032, driven by an aging population and increasing prevalence of related diseases.

    The APAC region, with a value of 1.2 billion USD in 2023 and anticipated growth to 2.5 billion USD by 2032, shows a significant opportunity for market expansion due to rising healthcare investments.South America, although smaller at 0.5 billion USD in 2023 and likely to rise to 1.1 billion USD by 2032, indicates growing accessibility to treatment options. Meanwhile, the MEA region, valued at 0.2 billion USD in 2023 with a forecast of 0.5 billion USD by 2032, remains the smallest segment but demonstrates potential for growth as healthcare infrastructure improves.

    Overall, these figures illustrate the varied landscape of the Global Apixaban Market segmentation and the opportunities that lie ahead in each region.

    Apixaban Market Regional Insights

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    Key Players and Competitive Insights

    The Global Apixaban Market has been witnessing significant interest and competition, shaped by the growing prevalence of thromboembolic disorders and the increasing need for effective anticoagulants. As a direct oral anticoagulant (DOAC), Apixaban is gaining traction due to its favorable efficacy and safety profile compared to traditional anticoagulants. The competition in the market is characterized by the presence of established pharmaceutical companies and emerging players focusing on research and development to enhance product offerings.

    With the expansion of indications and the increasing awareness regarding the management of atrial fibrillation and venous thromboembolism, the Global Apixaban Market continues to evolve, driven by innovation and strategic collaborations among key stakeholders.AstraZeneca can be distinguished within the Global Apixaban Market due to its robust research capabilities and a diverse portfolio that supports its positioning as a leader in the anticoagulation segment. The company has made significant investments in clinical trials, demonstrating the effectiveness of Apixaban in various patient populations, which has contributed to the product's acceptance among healthcare professionals.

    AstraZeneca's established distribution networks and strong marketing strategies enhance its market penetration and brand recognition. Additionally, its commitment to patient education and adherence programs has fostered trust and loyalty among patients, which is integral to sustaining long-term growth within this competitive landscape.Merck and Co hold a formidable position in the Global Apixaban Market, benefiting from its extensive experience in the pharmaceutical industry and a strong focus on research-driven innovation. The company has successfully leveraged its scientific expertise to develop high-quality anticoagulants that meet the evolving needs of patients and healthcare providers.

    Merck and Co’s proactive approach to regulatory affairs and its ability to navigate complex healthcare systems enable it to maintain a competitive edge. The company is also recognized for its efforts in promoting patient access to therapies and has implemented various initiatives aimed at increasing awareness about the importance of anticoagulant therapy. This strategic focus not only bolsters its brand reputation but also reinforces its commitment towards improving patient outcomes in the arena of anticoagulation therapies.

    Key Companies in the Apixaban Market market include

    Industry Developments

    • Q1 2024: Bristol Myers Squibb Announces U.S. FDA Approval of Updated Labeling for Eliquis® (apixaban) Bristol Myers Squibb announced that the U.S. FDA approved updated labeling for Eliquis (apixaban), reflecting new clinical data on its use for patients with nonvalvular atrial fibrillation.
    • Q2 2024: Pfizer and Bristol Myers Squibb Expand Eliquis® (apixaban) Manufacturing Capacity in North America Pfizer and Bristol Myers Squibb jointly announced the opening of a new manufacturing facility dedicated to increasing production capacity for Eliquis (apixaban) tablets in North America.
    • Q2 2024: Teva launches generic version of Eliquis in the U.S. Teva Pharmaceuticals announced the launch of its generic apixaban product in the United States following the expiration of certain patents, increasing competition in the anticoagulant market.
    • Q2 2024: Aurobindo Pharma receives FDA approval for generic apixaban Aurobindo Pharma received U.S. FDA approval to market its generic version of apixaban, expanding its portfolio of cardiovascular drugs in the U.S. market.
    • Q3 2024: Bristol Myers Squibb reports Eliquis® (apixaban) patent litigation settlement with generic manufacturers Bristol Myers Squibb disclosed a settlement agreement with several generic manufacturers regarding patent litigation for Eliquis (apixaban), allowing for earlier entry of generics in select markets.
    • Q3 2024: Pfizer announces new partnership with Indian pharmaceutical firm for apixaban distribution Pfizer entered into a partnership with an Indian pharmaceutical company to expand the distribution of apixaban in South Asia, aiming to increase access to anticoagulant therapies.
    • Q4 2024: Bristol Myers Squibb appoints new Executive Vice President for Cardiovascular Division Bristol Myers Squibb announced the appointment of a new Executive Vice President to lead its Cardiovascular Division, which oversees the Eliquis (apixaban) business.
    • Q4 2024: Natco Pharma launches generic apixaban in Europe Natco Pharma announced the launch of its generic apixaban product in several European countries, following regulatory approvals.
    • Q1 2025: Pfizer opens new research facility focused on anticoagulant innovation Pfizer inaugurated a new research facility dedicated to the development of next-generation anticoagulants, including research on apixaban derivatives.
    • Q2 2025: Bristol Myers Squibb announces strategic partnership with digital health company for apixaban patient monitoring Bristol Myers Squibb formed a strategic partnership with a digital health company to develop remote patient monitoring solutions for individuals prescribed apixaban.
    • Q2 2025: Hetero Labs receives EMA approval for generic apixaban Hetero Labs received European Medicines Agency (EMA) approval to market its generic apixaban product in the European Union.
    • Q3 2025: Aurobindo Pharma wins major hospital contract for apixaban supply in UK Aurobindo Pharma secured a significant contract to supply its generic apixaban to a network of hospitals in the United Kingdom.

    Future Outlook

    Apixaban Market Future Outlook

    The Apixaban Market is projected to grow at a 7.54% CAGR from 2025 to 2035, driven by increasing prevalence of thromboembolic disorders and rising demand for anticoagulants.

    New opportunities lie in:

    • Develop novel formulations to enhance patient adherence and convenience.
    • Expand market access through strategic partnerships with healthcare providers.
    • Leverage digital health technologies for personalized anticoagulation management.

    By 2035, the Apixaban Market is expected to achieve substantial growth, reflecting evolving healthcare needs and innovative solutions.

    Market Segmentation

    Apixaban Market End Use Outlook

    • Inpatient
    • Outpatient
    • Apixaban Market Regional Outlook

    Apixaban Market Regional Outlook

    • North America
    • Europe
    • South America
    • Asia Pacific
    • Middle East and Africa

    Apixaban Market Application Outlook

    • Atrial Fibrillation
    • Deep Vein Thrombosis
    • Pulmonary Embolism
    • Apixaban Market Formulation Outlook

    Apixaban Market Formulation Outlook

    • Tablets
    • Intravenous
    • Apixaban Market Distribution Channel Outlook

    Apixaban Market Distribution Channel Outlook

    • Hospitals
    • Retail Pharmacies
    • Online Pharmacies
    • Apixaban Market End Use Outlook

    Report Scope

    Report Attribute/Metric Details
    Market Size 2024    6.49 (USD Billion)
    Market Size 2025    6.98 (USD Billion)
    Market Size 2035 14.45 (USD Billion)
    Compound Annual Growth Rate (CAGR) 7.54% (2025 - 2035)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2024
    Market Forecast Period 2025 - 2035
    Historical Data 2020 - 2024
    Market Forecast Units USD Billion
    Key Companies Profiled AstraZeneca, Merck and Co, Sanofi, Eli Lilly and Company, AbbVie, Bristol Myers Squibb, Teva Pharmaceutical Industries, Boehringer Ingelheim, Gilead Sciences, Mylan, Roche, Johnson and Johnson, Pfizer, Novartis, Amgen
    Segments Covered Application, Formulation, Distribution Channel, End Use, Regional
    Key Market Opportunities Growing elderly population, Increasing prevalence of atrial fibrillation, Expanding use in thrombosis management, Rising demand for oral anticoagulants, Enhanced physician awareness and education
    Key Market Dynamics increasing prevalence of atrial fibrillation, growing geriatric population, rising awareness of anticoagulants, patent expirations and generics, robust pipeline of cardiovascular drugs
    Countries Covered North America, Europe, APAC, South America, MEA

    FAQs

    What is the expected market size of the Global Apixaban Market by 2034?

    The Global Apixaban Market is expected to be valued at 13.43 USD Billion by the year 2034.

    What is the expected CAGR for the Global Apixaban Market from 2025 to 2034?

    The Global Apixaban Market is expected to grow at a CAGR of 7.54% from 2025 to 2034.

    Which region is projected to hold the largest market share in the Global Apixaban Market by 2032?

    North America is projected to hold the largest market share, valued at 4.3 USD Billion by 2032.

    What are the key applications of Apixaban in the market?

    The key applications of Apixaban include Atrial Fibrillation, Deep Vein Thrombosis, and Pulmonary Embolism.

    How much is the Global Apixaban Market for Atrial Fibrillation expected to be valued at in 2032?

    The market for Atrial Fibrillation is expected to be valued at 4.32 USD Billion by 2032.

    What is the projected market size for Deep Vein Thrombosis application by 2032?

    The market for Deep Vein Thrombosis is projected to be valued at 3.22 USD Billion by 2032.

    Who are the major players in the Global Apixaban Market?

    Major players in the Global Apixaban Market include AstraZeneca, Merck and Co, Sanofi, and Bristol Myers Squibb.

    What is the expected market value for Europe in the Apixaban Market by 2032?

    The expected market value for Europe in the Apixaban Market is 2.8 USD Billion by 2032.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials